UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

_________________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

_________________

 

Date of Report (Date of earliest event reported): May 17, 2016

 

InspireMD, Inc.


(Exact name of registrant as specified in its charter)

 

Delaware

 

001-35731

 

26-2123838

(State or other
 jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

321 Columbus Avenue
Boston, MA

 

02116

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (857) 305-2410

 

 

  (Former name or former address, if changed since last
report)
 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01 Other Events.

 

On May 17, 2016, InspireMD, Inc. (the “Company”) issued a press release announcing that CGuard EPS reported positive results in PARADIGM-101, an investigator led clinical evaluation of the system or routine use in 101 consecutive, increased risk patients undergoing carotid artery stenting. The results of the study were presented at the EuroPCR 2016 Late-Breaking Clinical Trial Session in Paris, France. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)       Exhibits

 

Exhibit
Number
  Description
99.1   Press release dated May 17, 2016

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  InspireMD, Inc.
     
Date: May 17, 2016 By:   /s/ Craig Shore
    Name: Craig Shore
    Title: Chief Financial Officer